NCT06568289 Lignocaine vs Bupivacaine Infiltration for Postpartum Perineal Pain After Vaginal Delivery With Episiotomy in Primigravidae
| NCT ID | NCT06568289 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ain Shams University |
| Condition | Lignocaine |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2024-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-03-01 with a primary completion date of 2024-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, we will compare the effect and safety of lignocaine versus bupivacaine infiltration for postpartum perineal pain after vaginal delivery with episiotomy in primigravidae.
Eligibility Criteria
Inclusion Criteria: * Primigravidae with the full term undergoing vaginal delivery with episiotomy. * Pregnancies and singleton vertex cephalic fetuses. * In the active phase of the first stage of labor. Exclusion Criteria: * Patients with history of drug allergies to study drugs as this will increase the risk of complications. * Patients undergoing vaginal delivery under epidural or spinal anesthesia as they will affect post-operative pain and interfere with assessment of efficacy of local infiltration of the study drugs. * Evidence of local infection at site of injection as this will interfere with the action of the study drug and will increase the risk of complications. * Inability to cooperate as this will affect our assessment. * Patient's refusal. * Any intraoperative complications that will affect our outcome criteria (bleeding, organ injury) as they will affect patient's vital data and affect our assessment. * Neurological comorbidities (chronic pain disorder, chronic systemic disease, neurological disorder, neuropathic pain) as they will need more analgesia. * Drug abuse as they will be tolerant to the used analgesics.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06568289 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Lignocaine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06568289 currently recruiting?
Yes, NCT06568289 is actively recruiting participants. Contact the research team at mostafaserry15@gmail.com for enrollment information.
Where is the NCT06568289 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06568289 clinical trial?
NCT06568289 is sponsored by Ain Shams University. The trial plans to enroll 60 participants.